Deciphera Pharmaceuticals (NASDAQ:DCPH) Downgraded by ValuEngine

Share on StockTwits

ValuEngine cut shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a sell rating in a research note issued to investors on Saturday, ValuEngine reports.

DCPH has been the subject of several other research reports. Guggenheim increased their price target on shares of Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the company a buy rating in a research report on Tuesday, August 13th. Leerink Swann reissued a positive rating and set a $29.00 price target (up previously from $20.00) on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 14th. Cantor Fitzgerald increased their price target on shares of Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the company an overweight rating in a research report on Wednesday, August 14th. SunTrust Banks increased their price target on shares of Deciphera Pharmaceuticals to $60.00 and gave the company a buy rating in a research report on Wednesday, August 14th. Finally, Canaccord Genuity reissued a buy rating and set a $65.00 price target (up previously from $50.00) on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 14th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $50.27.

DCPH stock opened at $34.86 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. Deciphera Pharmaceuticals has a 52 week low of $18.55 and a 52 week high of $42.99. The firm’s fifty day moving average is $34.89 and its 200 day moving average is $27.34. The firm has a market cap of $1.73 billion, a P/E ratio of -12.36 and a beta of 1.89.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Friday, August 2nd. The company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.12) by $0.56. The business had revenue of $25.00 million for the quarter, compared to the consensus estimate of $20.00 million. As a group, analysts forecast that Deciphera Pharmaceuticals will post -4.05 EPS for the current year.

In other news, CFO Thomas Patrick Kelly sold 11,250 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $41.27, for a total value of $464,287.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel C. Martin sold 3,000 shares of the firm’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $35.56, for a total transaction of $106,680.00. Insiders have sold a total of 576,107 shares of company stock valued at $21,748,018 in the last three months. 7.02% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. lifted its position in shares of Deciphera Pharmaceuticals by 25.6% in the 2nd quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock worth $34,543,000 after purchasing an additional 311,870 shares during the period. Vanguard Group Inc. lifted its position in shares of Deciphera Pharmaceuticals by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 792,654 shares of the company’s stock worth $17,874,000 after purchasing an additional 20,252 shares during the period. Janus Henderson Group PLC lifted its position in shares of Deciphera Pharmaceuticals by 2.1% in the 2nd quarter. Janus Henderson Group PLC now owns 675,707 shares of the company’s stock worth $15,237,000 after purchasing an additional 14,028 shares during the period. Eversept Partners LP lifted its position in shares of Deciphera Pharmaceuticals by 21.9% in the 2nd quarter. Eversept Partners LP now owns 305,233 shares of the company’s stock worth $6,883,000 after purchasing an additional 54,801 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Deciphera Pharmaceuticals in the 2nd quarter worth about $4,606,000. 45.69% of the stock is owned by hedge funds and other institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Further Reading: Hedge Funds – Risk or Reward?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.